Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.
Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company's potential blockbuster drug for spinal muscular atrophy.
An experimental rheumatoid arthritis drug developed by Eli Lilly and Co and Incyte Corp poses serious risks of deadly blood clots at higher doses, U.S. Food and Drug Administration staff said on Thursday, the latest setback to a treatment regulators declined to approve last year.
UnitedHealth Group Inc , the largest U.S. health insurer, on Tuesday reassured investors that the pervasive flu season did not crimp first-quarter earnings as had been feared, boosting its shares as well as those of rivals.
Drugstore chain CVS Health Corp on Wednesday launched a new tool that will allow pharmacies help customers tackle the soaring cost of drugs by comparing prices of medicines.
Mylan NV will buy global marketing rights to an experimental multiple sclerosis treatment from Israel's Mapi Pharma, aiming to strengthen its position in the market for MS drugs and counter falling sales of its emergency allergy shot EpiPen.
Merck & Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market.
AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023.
Eli Lilly and Co's cancer drug Cyramza helped patients with liver cancer live longer, meeting the main goal of a late-stage trial, four years after failing a prior study.
Walgreens Boots Alliance Inc's quarterly profit and sales beat analysts' estimates on Wednesday helped by higher prescription volumes, but concerns surrounding its retail business played on investors' minds. | Video
- Gold: RPT-PRECIOUS-Palladium plunges as U.S. hints at Russia sanctions relief
- Oil Report: Court blocks Trump administration order delaying boost in fuel penalties
- British Pound Report: UPDATE 1-April gains prove to be brief for struggling sterling
- US Dollar Report: FOREX-Dollar jumps as U.S. 10-year bond yields approach 3 percent